Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics After Single Ascending Doses or Multiple Ascending Doses of OSCN-, bLF or ALX-009 in Healthy Male and CF and Non-CF Bronchiectasis Patients

NCT02598999 is registered in ClinicalTrials.gov with Alaxia SAS as lead sponsor.

NCT NCT02598999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02598999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics After Single Ascending Doses or Multiple Ascending Doses of OSCN-, bLF or ALX-009 in Healthy Male and CF and Non-CF Bronchiectasis Patients
Lead sponsor
Alaxia SAS
Phase
Phase 1
Overall status
Terminated
Start date
November 30, 2015
Completion date
December 31, 2021
Enrollment
92 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiectasis, cystic fibrosis